Herpes simplex myelitis
Methodology & AI Transparency ⓘ
Herpes simplex myelitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Herpes simplex myelitis (ICD-10-CM B00.82), Bacterial, Viral & Fungal Infections protocols prioritize antimicrobial stewardship (narrow-spectrum in Herpes simplex myelitis (B00.82: pathogen-directed duration) or) paired with baseline and interval Targeted PCR / in Herpes simplex myelitis (B00.82: Culture & Sensitivity) assessment.
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM B00.82 for Herpes simplex myelitis clinical workups.
- 3 Typical cash cost range: Workup highlights for Herpes simplex myelitis (B00.82): antimicrobial stewardship (narrow-spectrum in Herpes simplex myelitis (B00.82: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Objective lab/clinical target for Herpes simplex myelitis: Targeted PCR / in Herpes simplex myelitis (B00.82: Culture & Sensitivity) (Pathogen clearance / negative test (B00.82)) and Complete Blood Count in Herpes simplex myelitis (B00.82: (WBC & Differential)).
Ask our AI Specialists anything about Herpes simplex myelitis
What Is Herpes simplex myelitis?
For patients presenting with Herpes simplex myelitis (ICD-10-CM B00.82), Bacterial, Viral & Fungal Infections protocols prioritize antimicrobial stewardship (narrow-spectrum in Herpes simplex myelitis (B00.82: pathogen-directed duration) or) paired with baseline and interval Targeted PCR / in Herpes simplex myelitis (B00.82: Culture & Sensitivity) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in infections & antivirals, Herpes simplex myelitis (B00.82) involves cytokine pyrogen release [Herpes simplex myelitis B00.82]. progression correlates with shifts in Targeted PCR / in Herpes simplex myelitis (B00.82: Culture & Sensitivity) (Pathogen clearance / negative test (B00.82)).
Common Symptoms & Clinical Signs
- • Presentation of Herpes simplex myelitis (B00.82): painful vesicular rash in Herpes simplex myelitis (B00.82: in a dermatomal)
- • Secondary Herpes simplex myelitis clinical sign: regional lymph node in Herpes simplex myelitis (B00.82: tenderness or acute)
- • Symptom flares in Herpes simplex myelitis correlating with Targeted PCR / in Herpes simplex myelitis (B00.82: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (B00.82)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Herpes simplex myelitis (B00.82: pathogen-directed duration) or) evaluation (B00.82)
Herpes simplex myelitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B00.82 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: Targeted PCR / in Herpes simplex myelitis (B00.82: Culture & Sensitivity) | Pathogen clearance / negative test (B00.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Herpes simplex myelitis (B00.82: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B00.82) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Herpes simplex myelitis (B00.82: Procalcitonin) | Resolution to baseline (B00.82) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Herpes simplex myelitis
Treatment selection for Herpes simplex myelitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Herpes simplex myelitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster: What a 1,426-Participant Study Found In participants ≥50 years with prior HZ, RZV does not increase HZ recurrence risk. The Journal of infection • 2025-09-15 • Phase III Randomized Trial | N = 1,426 | 96/100 | PMID 40780591 ↗ |
| New Insights on A phase 3, randomized, gold-standard blind, compared against a dummy pill: What a 298-Participant Study Found Treatment-emergent side effects in both groups were generally mild in severity; there were two moderate events that were judged unrelated to study treatment, and no severe or serious events. The Journal of dermatology • 2023-03-15 • Phase III Randomized Trial | N = 298 | 93/100 | PMID 36353762 ↗ |
| New Insights on Patterns of staying on track with medication to a Dapivirine Vaginal Ring for: What a 626-Participant Study Found Most South African women successfully persisted with a moderate or high level of use. Journal of acquired immune deficiency syndromes (1999) • 2022-08-01 • Phase III Randomized Trial | N = 626 | 93/100 | PMID 35344520 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase III, multicenter, gold-standard blind, randomized clinical trial to In Chinese adult participants with cIAI, C/T plus metronidazole was noninferior to meropenem, with comparable safety. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35987467 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of a China-developed live attenuated herpes zoster vaccine in The trial included 25 000 participants. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2026-01-15 • Phase III Randomized Trial | N = 13 | 88/100 | PMID 40962113 ↗ |
Herpes simplex myelitis Patient Community & “People Like Me” Threads
Filter Herpes simplex myelitis community threads and patient logs by age, biological sex, dosage, and treatment duration.